Toronto Dominion Bank Acquires 7,688 Shares of DexCom, Inc. (DXCM)

Toronto Dominion Bank raised its holdings in DexCom, Inc. (NASDAQ:DXCM) by 64.6% during the 1st quarter, Holdings Channel reports. The institutional investor owned 19,588 shares of the medical device company’s stock after acquiring an additional 7,688 shares during the quarter. Toronto Dominion Bank’s holdings in DexCom were worth $2,333,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of DXCM. Norges Bank acquired a new stake in DexCom in the 4th quarter valued at $107,191,000. Vanguard Group Inc grew its position in shares of DexCom by 11.5% in the 3rd quarter. Vanguard Group Inc now owns 7,942,861 shares of the medical device company’s stock valued at $1,136,147,000 after acquiring an additional 816,247 shares during the period. Two Sigma Advisers LP grew its position in shares of DexCom by 1,493.1% in the 4th quarter. Two Sigma Advisers LP now owns 694,814 shares of the medical device company’s stock valued at $83,239,000 after acquiring an additional 651,200 shares during the period. Two Sigma Investments LP grew its position in shares of DexCom by 596.5% in the 4th quarter. Two Sigma Investments LP now owns 731,059 shares of the medical device company’s stock valued at $87,581,000 after acquiring an additional 626,098 shares during the period. Finally, MERIAN GLOBAL INVESTORS UK Ltd bought a new position in shares of DexCom in the 4th quarter valued at about $65,247,000.

Several analysts recently commented on the stock. BidaskClub downgraded shares of DexCom from a “buy” rating to a “hold” rating in a report on Tuesday, March 26th. Zacks Investment Research upgraded shares of DexCom from a “hold” rating to a “buy” rating and set a $138.00 price objective for the company in a research note on Monday, May 6th. BMO Capital Markets lifted their price objective on shares of DexCom from $167.00 to $172.00 and gave the stock an “outperform” rating in a research note on Thursday, May 2nd. Raymond James dropped their price objective on shares of DexCom from $160.00 to $150.00 and set an “outperform” rating for the company in a research note on Thursday, May 2nd. Finally, Piper Jaffray Companies lifted their price objective on shares of DexCom to $173.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 1st. Five investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $152.25.

In related news, EVP Donald Abbey sold 7,653 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $142.79, for a total transaction of $1,092,771.87. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Patrick Michael Murphy sold 400 shares of the company’s stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $115.05, for a total transaction of $46,020.00. The disclosure for this sale can be found here. Insiders sold a total of 94,863 shares of company stock valued at $12,990,071 over the last 90 days. Corporate insiders own 1.80% of the company’s stock.

Shares of NASDAQ:DXCM traded up $2.35 during midday trading on Friday, hitting $116.81. The stock had a trading volume of 5,155 shares, compared to its average volume of 1,308,686. The stock has a market capitalization of $10.81 billion, a PE ratio of 387.17 and a beta of 0.73. The company has a current ratio of 7.18, a quick ratio of 6.75 and a debt-to-equity ratio of 1.57. DexCom, Inc. has a fifty-two week low of $86.32 and a fifty-two week high of $156.16.

DexCom (NASDAQ:DXCM) last issued its earnings results on Wednesday, May 1st. The medical device company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.12. The company had revenue of $280.50 million during the quarter, compared to analysts’ expectations of $246.10 million. DexCom had a negative net margin of 11.51% and a positive return on equity of 8.45%. The business’s revenue for the quarter was up 52.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.30) EPS. On average, research analysts predict that DexCom, Inc. will post 0.77 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Toronto Dominion Bank Acquires 7,688 Shares of DexCom, Inc. (DXCM)” was first published by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://www.baseballdailydigest.com/news/2019/05/24/toronto-dominion-bank-acquires-7688-shares-of-dexcom-inc-dxcm.html.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Read More: Net Income

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.